Antengene and Wuxi Biologics enter into a strategic collaboration.
Antengene Corporation and WuXi Biologics have recently signed a strategic cooperation Memorandum of Understanding (MoU) to collaborate on the development and production of novel drugs and jointly promote the R&D of innovative oncology therapies.
Through the joint collaboration, Antengene and WuXi Biologics will make full use of their extensive resources and professional capabilities to accelerate the research and development of innovative cancer therapies and provide patients with high-quality and affordable treatment plans for patients around the world.
Both companies are delighted with the establishment of strategic cooperation in accelerating the research and development process of innovative oncology therapies.
Samsung Biologics enters into a partnership with Dinona.
Samsung Biologics has entered into a partnership agreement with Dinona, a Biotechnology company. This is to further expand its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing.
Under this partnership, Samsung and Dinona will collaborate for the fast-track development of DNP-019, a COVID-19 antibody therapy candidate.
Samsung Biologics has recently been aggressive in expanding its CDO sector with over 50 new agreements signed in the last two years. They have also just recently launched its proprietary cell-line technology, S-CHOice, this year showing improved titers up to two-fold from the industry average and maintaining over 90% cell viability.
Edesa Biotech gets clearance from FDA for Monoclonal Antibody drug targeting COVID-19.
Edesa Biotech has recently received clearance from the US Food and Drug Administration (FDA) to commence the Phase 2/3 clinical study for a candidate drug treating COVID-19 patients.
The candidate drug is called EB05, a monoclonal antibody that could potentially regulate the overactive immune responses induced by Acute Respiratory Distress Syndrome (ARDS).
Patients in the clinical study will be receiving a single dose of the investigative drug. The phase 2/3 clinical study will be held in an adaptive, multicenter, randomized, double-blind, placebo-controlled manner to evaluate the safety and efficacy of the drug towards adults at risk of ARDS.
Edesa Biotech currently has two monoclonal antibodies, EBO5 and EB06 in their pipeline as potential COVID-19 treatments.